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Abstract
Leishmania infantum causes zoonotic visceral leishmaniasis (ZVL) in the Mediterranean
basin and South America. The parasite has been shown to co-infect HIV patients and an
outbreak in central Spain was reported in the last decade. Therfore, ZVL is a public health
problem, dogs being the parasite’s reservoir. We have developed a DNA vaccine based on
the L. infantum activated protein kinase A receptor (LACK) using different plasmid vectors
and vaccinia virus strains as vehicles. Recently, we have generated an antibiotic resistance
marker-free plasmid vector called pPAL. Homologous pPAL-LACK prime-boost vaccination
protects Beagle dogs as well as a heterologous plasmid-virus regime. For both reasons,
pPAL improves safety. IL12 was described to trigger Th1 response through IFN-? produc-
tion in infected dogs, being a good candidate for cytokine therapy in conventional treatment-
unresponsive dogs. Herein, we report a complete protection study in dogs through inocula-
tion of genes encoding for the p35 and p40 subunits which compose canine IL12 in combi-
nation with the LACK gene. A homologous plasmid-plasmid regime using independent
pPAL constructs for each gene was inoculated in a 15-day interval. The infectious challenge
using L. infantum promastigotes was successful. The outcome was pPAL-LACK vaccine
protection suppression by IL12 administration. The important implications of this finding are
discussed in the manuscript.
Introduction
Leishmaniasis is a disease caused by trypanosomatid parasites grouped into the genus Leish-
mania. Human leishmaniasis is classified according to the clinical manifestations into cutane-
ous (CL), mucocutaneous (MCL), and visceral leishmaniasis (VL). VL by Leishmania
infantum is a zoonosis (ZVL), whereas VL by Leishmania donovani is anthroponotic. VL is
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fatal without treatment and causes about 50,000 annual deaths worldwide [1]. HIV-Leish-
mania co-infections have been reported [2,3,4,5,6]. Canids are L. infantum (syn. L. chagasi)
reservoirs in the Mediterranean basin, Central Asia and South America [7,8]. An L. infantum
outbreak has been registered in humans during the last decade in central Spain [9,10,11,12,
13,14]. As a difference with human VL, variable cutaneous and visceral clinical signs simulta-
neously occur in dogs depending on the individual. The clinical profiles range from asymp-
tomatic to severe, including weight loss, asthenia, cutaneous lesions, conjunctivitis, anorexia,
lymphadenopathy, hepatomegaly, splenomegaly, etc. [15,16,17]. Bone marrow may become
densely parasitized in infected dogs, causing histiocytic hyperplasia, erythrocytic hypoplasia,
granulomas, and megakaryocytic emperipolesis and dysplasia [18].
Leishmania spp. parasites develop a digenetic life cycle defined by two stages. Promastigotes
are fusiform motile cells with a flagellum emerging from the cellular body anterior pole. This
stage differentiates in the gut of sand flies (Psychodidae: Phlebotominae) from procyclic to
highly infective metacyclic forms. Simultaneously, promastigotes migrate towards the anterior
gut. Metacyclic promastigotes are inoculated in the mammalian host’s dermis during blood-
meal intakes. A few promastigotes not cleared by the complement system are internalized by
phagocytic mononuclear cells, where they differentiate to the obligate intracellular amastigote
stage and multiply inside phagolysosomes. Amastigotes are released when the host cell
colapses and are able to infect other phagocytes. A sand fly becomes infected when feeding
from an infected mammal’s blood (reviewed by Moody [19]). The immune response against
Leishmania spp. is partially understood only in the mouse-L.major infection model. In this
case, lymphocyte T helper response type 1 (Th1) leads to protection, whereas Th2 leads to sus-
ceptibility [20]. Interleukin 10 (IL10) is able to inhibit interferon-? (IFN-?) and IL12 produc-
tion, leading to susceptibility [21]. IL12 is a proinflammatory cytokine against intracellular
pathogens. The Th1/Th2 dichotomy is absent in canine leishmaniasis and human CL and VL.
For example, IFN-? decreases in humans at the early CL infection stages [22], but gradual
IFN-? and tumoral necrosis factor ? (TNF-?) increase is observed, leading to self-healing over
time [21]. A balanced Th1/Th2 response seems to trigger protection against L. infantum in
dogs, as suggested by ?-IFN and IL10 patterns [23,24,25,26,27]. IL12 is able to trigger IFN-?
production in peripheral blood mononuclear cells (PBMC) of L. infantum infected dogs [28].
For this reason, treatment with IL12 may lead to healing.
The L.infantum activated protein kinase A receptor analogue (LACK) is located in the cyto-
plasm particulate fraction [29], and is able to protect BALB/c mice against L.major [30,31]
and L. infantum [32], and Beagle dogs against L. infantum [27,33,34] experimental infection
when administered as a DNA vaccine. The antibiotic resistance marker-free mammalian
expression plasmid vector pPAL has been used as a new vaccination vehicle for the LACK
gene. The pPAL-LACK vaccine is approximately as efficacious against canine leishmaniasis
when administered following a plasmid-plasmid homologous regime as when an heterologous
plasmid-recombinant vaccinia virus regime is followed [26]. Efficacy is higher by the intrana-
sal than by the subcutaneous route in mice [35] and in dogs [26]. The aim of the present study




A bone marrow explant from a naturally infected retriever dog was cultured at 26˚C in NNN
(Novy–Nicolle–McNeal) medium in order to axenize L. infantum promastigotes (isolate
MCAN/ES/MON1/Z001), which hold genotype A and zymodeme MON-1 (Maribel Jime´nez
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and Ricardo Molina, personal communication) according to ITS- [36] and CPB-based [37]
genotyping and zymodeme determination [38,39]. Promastigotes were transferred to complete
medium (CM) composed of RPMI 1640 supplemented with 2mM glutamine (Gibco BRL) and
10% of heat-inactivated (56˚C, 1h) fetal bovine serum (Cambrex). 100μg of streptomycin and
100IU penicillin/ml (Gibco BRL) were added to the culture media. Stationary phase (day 7)
promastigotes were obtained for challenge four passages after bone marrow explant
cultivation.
Crude L. infantum antigen (CLA) was obtained from 8x108 cell/ml stationary phase pro-
mastigote suspension in PBS applying three freezing-thawing cycles (-20˚C/room tempera-
ture). Soluble leishmania antigen (SLA) was prepared by CLA sonication followed by
centrifugation at 16,000xg for 3min. Recombinant LACK protein was expressed in heterolo-
gous system and purified as follows using a pRSETB-LACK E. coli BL21 pLysS clone obtained
by Gonza´lez-Aseguinolaza et al. [29]: i) growth of a 20mL inoculum at 37˚C for 16h in liquid
LB medium containing 100μg/mL ampicillin; ii) dilution to 1L LB-ampicillin and growth until
reaching 0.5 OD600nm; iii) 1h induction with 1M IPTG; iv) centrifugation at 4,000g for 20 min;
v) pellet re-suspension and mild agitation in 10mL of buffer A (6M guanidine hydrochloride,
0.1M NaH2PO4, and 10mM Tris-HCl, pH 8.0; vi) centrifugation at 10,000xg for 30min; vii)
equilibration of 3mL Ni-NTA resin (Qiagen) with 10mL buffer A; viii) batch incubation of the
resin with the supernatant obtained in step vi for 1h at room temperature; ix) resin packaging
on column and lysate elution; x) wash with 8mL buffer B (8M urea, 0.1M NaH2PO4, and
10mM Tris-HCl, pH 8.0); xi) two additional wash steps with 4mL buffer C (8M urea, 0.1M
NaH2PO4, and 10mM Tris-HCl, pH 6.3); xii) elution with 10mL buffer D (8M urea, 0.1M
NaH2PO4, and 10mM Tris-HCl, pH 5.9); xiii) elution with 10 ml buffer E (8M urea, 0.1M
NaH2PO4, and 10mM Tris-HCl, pH 4.5). In all elution steps, 2.5mL fractions were collected.
All steps were analyzed by 12% SDS-PAGE. For this purpose, 0.1% uninduced/induced culture
volume aliquots were centrifuged at 13,000xg for 1min and resuspended in 30μL Laemmli
loading buffer; or 20μL eluate aliquots were taken, diluted to 180μL with PBS, precipitated at
4˚C for 15min with trichloroacetic acid (adding 20μL of a 50% stock solution), centrifuged at
15,000g for 15 min, washed with 200μL pre-cooled absolute ethanol, air-dried, and resus-
pended in Laemmli loading buffer. Purified LACK protein fractions were dialyzed three times
against PBS (30min each), and finally against 0.1% SDS in PBS for 16h. CLA, SLA, and LACK
antigens were quantified by the Bradford method.
pPAL-LACK, pPAL-IL-12p35 and pPAL-IL-12p40 plasmid constructs
The pPAL-LACK third generation vaccine was generated as described [26,40]. Canine
IL12-p35 and p40 subunit gene ORFs (GenBank accession numbers U49085 and U49100)
flanked by appropriate restriction sites were chemically synthesized and delivered in pGH
plasmid vector (ATG Biosynthetics): MluI site in the 5’ end of both genes, SalI site in the
canIL12-p35 3’ end, and XbaI site in the canIL12-p40 3’end. E. coli XL1-blue competent cells
were prepared following the procedure described by Hannahan et al. [41] and each 100μL cell
aliquot transformed with 10μL of a 0.5ng/μL plasmid solution by a heat shock procedure as fol-
lows: i) 4˚C for 20min; ii) 37˚C for 1min; iii) 4˚C for 2min; iv) 37˚C for 1h after dilution with
LB liquid medium. 10% of the transformation mix volume was plated onto LB-agar containing
100μg/mL ampicillin. Positive clones of each construct were then expanded at 37˚C for 16h in
20ml liquid LB medium in the presence of 100μg/ml ampicillin and purified with High Pure
Plasmid Isolation Kit (Roche) following the manufacturer’s instructions.
pGH-canIL12-p35 plasmid was digested with MluI/SalI at 37˚C for 1 h using NEB3 buffer
and 0.1mg/mL BSA. The same conditions were applied to digest pPAL with MluI/SalI. The
IL-12 failure as vaccine adjuvant against canine leishmaniasis
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desired digests were isolated by 1% agarose gel electrophoresis. The bands were excised and
purified with QIAquick Gel Extraction Kit (Qiagen), and the 50μL eluate was diluted to 100μL
with milliQ water and precipitated with 0.1 volume of 3M sodium acetate and 2.5 volumes of
pre-chilled absolute ethanol at -20˚C for 30 min. The mixture was centrifuged at 15,000xg for
20min and the pellet washed with 70% ethanol, air dried and resuspended in 25μl of milliQ
water. The same digestion and purification process was followed for pGH-canIL12-p40 and
pPAL using only MluI in NEB3 buffer because MluI and XbaI are not compatible for digestion
in the same NEB buffer. Once pGH-IL12-p40 and pPALMluI digests were purified, the entire
process was repeated with XbaI. Inserts and vectors were quantified by 260nmUV spectropho-
tometry and densitometry of 1% agarose gel electrophoretic runs. The ligation reactions of
insert with 50ng vector at a 5:1 molar ratio were performed at room temperature for 1h using
400Weiss units of T4-DNA ligase and buffer (NEB) in a final volume of 10μL. Ligation mix-
tures were used to transform the E. coli SURE strain (Agilent Technologies) following the
manufacturer’s instructions. 10% of total transformation mixture volumes were plated onto
LB-agar containing 5μM triclosan and grown at 37˚C for 16h. Clone expansion and plasmid
isolation was performed as specified above. Recombinant clones were selected by 1% agarose
gel electrophoresis analysis and confirmation was performed by Sanger sequencing. A selected
recombinant clone of each construct (pPAL-canIL12-p35 and pPAL-canIL12-p40) was grown
in the presence of 5μM triclosan and purified using Endotoxin-Free Qiagen Plasmid Mega Kit
(Qiagen). Plasmid quantification was performed as specified above. pPAL-canIL12-p35 and
p40 plasmid maps and sequences are shown in S1 and S2 Figs.
Animals, ethical statements, plasmid inoculation and infectious challenge
All measures available to ameliorate suffering of five female and five male 12-18-month old
~13 Kg beagle dogs (CEDS) used in the experiment were taken. Dogs were lodged, maintained,
and used for experimentation at optimal conditions: temperature control, ad-libitum feeding,
procedure refinement, disease monitoring, behavioral enrichment, daily controlled release
outdoors, etc. Experimental design and procedures included in project [Safety, immunogenic-
ity, and efficacy study of the DNA vaccine pPAL-LACK after challenge with Leishmania infan-
tum in dogs] were approved by the University of Zaragoza Ethical Advisory Commission for
Animal Experimentation (11/03/2010, reference PI12/10). Two animal groups were set: i)
group 1 (GI), PBS-dissolved 200μg pPAL-LACK + 20μg pPAL-canIL12-p35 + 20μg pPAL-
canIL12-p40 prime-boost inoculation by the intranasal route (60 and 45 days before chal-
lenge); and ii) challenged control group (group 2, GII). Challenge was performed by the i.v.
route with 108 L. infantum stationary phase promastigotes. 2-mL blood samples were taken 60
days before and 40 days after experimental infectious challenge (-60 dpi and 40dpi) for
humoral response analysis. 10-mL blood samples were extracted -7, 21, 180, 240, and 300 dpi
for humoral and cellular immune response analysis. 100-μL bone marrow samples were
obtained 0, 21, 180, and 240 dpi for parasite burden analysis. At the end of the study (300dpi),
dogs were euthanized using 0.3ml/kg T61 (Intervet) by the intravenous route. Liver, lymph
node, bone marrow, and spleen samples were collected during necropsy for parasite burden
and cellular immune response analysis.
Evaluation of clinical signs
Canine leishmaniasis clinical signs (alopecia, anemia, diarrhea, exfoliative dermatitis, epistaxis,
hepatomegaly, splenomegaly, keratoconjunctivitis, lethargy, lymphadenopathy, muscular atrophy,
onychogryphosis, seborrheic dermatitis, skin ulcers, weight loss, etc.) were registered in clinical
record forms. Intensity of every clinical sign was scored in a natural number scale ranging from 0
IL-12 failure as vaccine adjuvant against canine leishmaniasis
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to 5. Numerical evaluation of clinical signs (NECS) is an approximation to illustrate the overall
dog clinical profile which is calculated as the sum of all scores registered in an animal.
Parasite burden evaluation
Genomic DNA was isolated from bone marrow aspirates using NucleoSpin1 Blood
(Macherey-Nagel) following the manufacturer’s instructions. Francino et al. [42] LEISH-1
primer (???????????????????????), LEISH-2 primer (?????????????????), and
LEISH-P TaqMan MGB probe (????????????????????????) distributed onto
384-well plates using the Assays-by-Design service (Applied Biosystems, Life Technologies)
were used for quantitative parasite burden evaluation. Reactions were performed in a 7900HT
Fast Real Time PCR system (Life Technologies) using 2x TaqMan1 Universal Master Mix
(Life Technologies) and genomic DNA template 1:5 serial dilutions (1, 0.2, and 0.04ng/μl) in a
final volume of 10μL. Thermal cycling was carried out as follows: 95˚C for 5min; 40x[95˚C for
30s; 60˚C for 1min, data acquisition]. Two technical replicates per sample were performed.
Eukaryotic 18S rRNA Pre-Developed Taqman Assay Reagents (Applied Biosystems, Life Tech-
nologies) were used as endogenous reference performing the same sample dilutions and tech-
nical replicates. Precautions to avoid contamination with external DNA were taken at all times
throughout the experiments, including separate reagent and sample manipulation and storing
locations, as well as surface decontamination using 10% bleach. Coefficients of variation were
checked (20%), and PCR efficiencies were calculated using the linear regression method.
Raw quantities are efficiencies to the power of negative Ct. Normalized quantities were
obtained by dividing LEISH by 18S rRNA quantities. Best fit equation obtained from linear
regression of absolute quantification standards was applied to calculate the number of parasites
in 10ng sample. The number of amastigotes per mg tissue was estimated using a correction fac-
tor based on genomic DNA purification yield.
Humoral immune response assessment
2-mL peripheral blood collected from dogs were allowed to clot at room temperature for 20min
using Eurotubo1 Serum Separation polypropylene tubes (Deltalab) with accelerant and gran-
ules, and centrifuged at 1,000xg at room temperature for 10min. Serum was stored at -20˚C and
used for ELISA assessment of total IgG, IgG1 and IgG2 levels. First, 96-well flat-bottommicro-
plates were coated with 100μl of 10μg/mL SLA in 3.36mM carbonate– 10mM bicarbonate buffer
at 4˚C overnight, blocked with 1% BSA in PBS, and washed three times with 0.1% BSA, 0.03%
Tween 20 in PBS. Next, 100μL of 1:10 serum sample was added to each well and allowed at
room temperature for 30min. Meanwhile, HRP-conjugated anti-dog IgG1 and anti-dog IgG2
antibodies (Bethyl Laboratories) were respectively diluted 1:15,000 and 1:20,000 in blocking
solution, and protein A (Sigma-Aldrich) was prepared at 0,19μg/mL using washing solution.
Samples were washed before and after incubation with 100μL of the corresponding antibody or
protein A solution at room temperature for 2h, although the last washing step was carried out
with PBS. An O-phenylendiamine dihydrochloride (OPD) tablet was dissolved in 12mL of cit-
rate buffer (5.2mM citric acid, 12.7mMNa2HPO4, pH 5.0) and 15μL H2O2 were added. Color
development was allowed for 20min after adding 100μL of this solution to each well. The reac-
tions were stopped by adding 50μL of 1% SDS, and absorbance was read at 450nm using Micro-
plate Reader 680 (BioRad) and Microplate Manager 5.2.1. software (BioRad).
Lymphoblastic transformation test (LTT)
Peripheral blood samples (8mL) were collected in lithium-heparin BD Vacutainer1 tubes
(BD Biosciences). Once blood samples were diluted with 10mL PBS, peripheral blood
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mononuclear cells (PBMC) were isolated by centrifugation over 7mL LymphoprepTM (1.077g/
mL, Axis-Shield) at 750xg (no brake) at room temperature for 30min. Target organ (liver,
lymph node, or spleen) ~0.5cm3 portions were disaggregated using BD Falcon Cell Strainers
(BD Biosciences) Buffy coats or target organ cell suspensions were washed in 50mL PBS, incu-
bated in 1mL erythrocyte lysis solution (0.15M NH4Cl, 10mM KHCO3, 0.1mM EDTA, pH
7.2) for 10min, labelled with 10μg/mL carboxyfluorescein succinimidyl ester (CFSE, Molecular
Probes) during 20min, washed with RPMI twice, and cultured at 37˚C in the presence of 5%
CO2 for 3 days in CM containing 50μg of ?-mercaptoethanol in the presence of different sti-
muli (1μg/mL concanavalin A, 10μg/mL denatured recombinant LACK protein, or no stimu-
lus). Then, cells were harvested in 96-deep-well plates (Eppendorf), supernatants stored at
-20˚C and pellets washed twice in 1% BSA in PBS, blocked in the same solution for 1h, and
incubated with ~0.1mg/mL R-phycoerythrin (RPE)-conjugated rat anti-canine CD4 (Serotec),
once each vial’s content had been dissolved in 1 ml milliQ water and this solution 1:10 diluted
using 1% BSA in PBS. Next, cells were harvested, washed, and resuspended in a solution con-
taining 0.5% BSA and 0.003% sodium azide in PBS. Flow cytometry analysis was carried out
with a Cytomics Beckman Coulter FC 500 Cytometer. For this purpose, an area located in the
low right quadrant of the FSC-SSC plot, where lymphoblast signals are expected, was gated.
CFSE and RPE fluorescent signals were collected using 488nm and 635nm laser excitation
wavelengths. The percentage of CD4+ CFSE-negative cells was registered, and no-stimuli con-
trol values were substracted to CLA- and LACK- stimulated culture aliquots.
Quantification of IL-10 and IFN-? in LTT supernatants
Canine IL-10 and IFN-?DuoSet1 ELISA Development System (R&D Systems) kits were used
following the manufacturer’s specifications. In summary, antibodies, standards and other
reagents were reconstituted and/or stored as specified in the certificates of analysis, flat-bottom
96-well microplates were coated with 100μL PBS-diluted Mouse Anti-Canine IL10/IFN-? Cap-
ture Antibody (according to the Certificate of Analysis), and the plates sealed and incubated
overnight at room temperature. Then, three 400-μL washes were performed with 0.05%
Tween 20 in PBS (pH 7.4), blocking with 300 μL Reagent Diluent (0.2 μm-filtered 1% BSA in
PBS) was allowed at room temperature for 1h, and the washing cycles were repeated. Next,
LTT supernatant samples and standards (100μL each) were added to the corresponding wells
and incubated at room temperature for 2h after sealing the plate. For this purpose, standard
dilutions were performed using Reagent Diluent. Then, washes were repeated and 100μL Bioti-
nylated Mouse Anti-Canine Detection Antibody diluted with PBS in Reagent Diluent (accord-
ing to the Certificate of Analysis) were added to all wells, and incubated at room temperature
for 2h. Once washes were repeated, 100μL Streptavidin-HRP solution (prepared at a dilution
specified in the vial using Reagent Diluent) were added to each well and incubated at room
temperature in the dark for 20min. Next, washes were repeated and a 20-min room-tempera-
ture incubation in the dark with 100μL Substrate Solution (1:1 Color Reagents A and B–
respectively, H2O2, and tetramethylbenzidine; R&D Systems). The reactions were stopped
using 2N H2SO4. Absorbance at 450 nm was monitored with Microplate Reader 680 (BioRad)
and Microplate Manager 5.2.1. software (BioRad).
Results
Clinical signs
Outstanding differences in clinical profiles between the control (GII) and the pPAL-LACK/
pPAL-canIL12p35/pPAL-canIL12-p40-inoculated group (GI) were not observed over time
(Fig 1). In fact, some dogs in both groups became increasingly sick over time and had to be
IL-12 failure as vaccine adjuvant against canine leishmaniasis
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euthanized for ethical reasons before the end of the experiment, while others did not develop
any serious clinical sign associated to leishmaniasis (e.g. absence of splenomegaly but presence
of mild lymphadenopathy and skin lesions). Early necropsy procedures were performed after
240 dpi. All other dogs were euthanized 300dpi as planned in the experimental design. All end
time point data were processed together.
Parasite burden
The parasite burden in bone marrow measured as number of amastigotes per mg of tissue
increases in the vaccinated and inthe control group (GII) over time (Fig 2). These observations
demonstrate that the experimental infectious challenge was effective. The median is lower in
the vaccinated group than in the control group 180dpi, but is approximately equal in both
groups 240 dpi, although data are quite more disperse and the maximummuch higher in the
control group, GII (Fig 2). Analysis at the end of the experiment (~300 dpi, see Fig 3) revealed
that the parasite burden profile is reversed with respect to initial data. The parasite burden
medians in bone marrow, lymph node, spleen, and liver are higher, although dispersion and
maxima are wider in bone marrow and spleen (Fig 3). Nonetheless, differences are not statisti-
cally significant according to statistical inference using the non-parametric Mann-Whitney U
test (? = 0.05), which is caused by intra-group differences between individuals. Therefore,
inoculation of a primer and a booster dose of the mixture composed of 200μg pPAL-LACK,
20μg pPAL-canIL12-p35, and 20μg pPAL-canIL12-p40 constructs does not generally lead to
significant reduction of parasite burden than in the challenge control group (GII). However,
Fig 1. Numerical evaluation of clinical signs (NECS). Clinical signs were evaluated 150, 180, 240, and 300 dpi. GI: dogs which received
two doses of 200μg pPAL-LACK + 20μg pPAL-canIL12-p35 + 20μg pPAL-canIL12-p40. GII: infection control group. Represented values
are the sum of 0–5 scores provided to each of the clinical signs observed. Positive standard deviations have been represented. Several
dogs had to be euthanized before the end of the experiment (after the 240dpi time point) for ethical reasons.
https://doi.org/10.1371/journal.pone.0212136.g001
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partial protection is observed at 180dpi, according to the considerably lower parasite burden
values and range in group I.
Humoral immune response assessment
Leishmania-specific IgG1, IgG2, and total IgG level follow-up throughout the experiment
revealed absence of Leishmania-specific antibodies at the beginning of the experiment and a
gradual increase after challenge, reaching the plateau around 120dpi (Fig 4). These are addi-
tional data demonstrating the effectiveness of the experimental infectious challenge. No statis-
tically significant differences (Mann-Whitney U test, ? = 0.05) in the IgG isotype circulating
levels were observed between the experimental (GI) and the control (GII) group, including
total IgG and IgG1 and 2 subclasses.
Cellular immune response analysis
Lymphoblastic transformation of PBMC in the presence of recombinant LACK protein is
observed -7dpi (53 days after prime inoculation and 38 days after administration of the boost
dose) in pPAL-LACK/pPAL-canIL12p35/pPAL-canIL12-p40-inoculated dogs (group I), but
not in the control group, GII (Fig 5). The proliferation median is ~8%, which decreases to
~3% shortly after challenge (21dpi), and is maintained around ~1% until the end of the experi-
ment. No CD4+ proliferation in the presence of the LACK protein is observed in group II. The
differences between both groups are statistically significant (Mann-Whitney U test, ? = 0.05).
Cytokine profile analysis of LTT supernatants has revealed fluctuations in the IFN-? and
IL10 levels of proliferating PBMC in both groups (Figs 6 and 7). Two IFN-? peaks are
observed in group I. The second peak is simultaneous to the decrease in group II. Conversely,
group II shows relatively high IFN-? levels at the beginning of the experiment compared to the
almost inexistent levels in group I (21dpi), which turn out to be approximately equal in both
groups 120dpi (Fig 6). There is an IL10 peak in both groups, which was observed earlier in
group I (Fig 7).
Fig 2. Parasite burden in bone marrow throughout the vaccination experiment. The number of amastigotes per mg tissue at 21, 180,
and 240dpi is represented. The experimental infectious challenge using L. infantum promastigotes was effective. Parasite burden is
higher in the infection control group (GII) than in the pPAL-LACK/pPAl-canIL12-p35/pPAL-canIL12-p40 inoculation group (GI).
https://doi.org/10.1371/journal.pone.0212136.g002
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Discussion
The LACK antigen gene administered in a mammalian expression plasmid vehicle is able to
partially protect mice against infection by L.major (cutaneous signs) [30,31]. This was also
observed in dogs against L. infantum infection (cutaneous and visceral signs) and was
improved using a recombinant plasmid in the prime dose and a recombinant vaccinia virus in
the booster dose by the subcutaneous route [27,33,34]. The intranasal administration route
was shown to be more effective than the subcutaneous route in the murine model when
administering naked DNA [35]. More recently, we have improved safety using the antibiotic
resistance-free plasmid pPAL as the LACK gene vehicle by the intranasal route [26]. This safety
improvent has two contributions. First, antibiotic resistance genes were removed. Second, the
E. coli fab I gene used to replace them as a selection marker contains a long CpG island which
hypothetically acts as an adjuvant. In fact, pPAL-LACK prime-boost vaccination administered
by the intranasal route approximately protects as well as an heterologous regime which con-
sists of using the same plasmid as the primer and the recombinant modified vaccinia virus
Ankara strain (MVA-LACK) as the booster [26]. Using the dog model for studying L.
Fig 3. Parasite burden in target organs at the end of the experiment. Parasite burden is similar in GI (pPAL-LACK/pPAL-canIL12-p35/pPAL-
canIL12-p40 group) and GII (infection control group), or higher in GI than in GII, depending on the organ. Individual variability contribute to data
dispersion. Several dogs had to be euthanized before the end of the experiment (after the 240dpi time point) for ethical reasons.
https://doi.org/10.1371/journal.pone.0212136.g003
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infantum infection and for vaccination trials is challenging for a variety of reasons. Some are
related with lodging, animal care, and suffering amelioration, complying with animal experi-
mentation regulations. Others are related with genetic variability and reduced sample number
intrinsic to experimentation. However, using this model is essential because results in more
conventional laboratory animal models cannot usually be extrapolated to the canine model,
which acts as the natural reservoir in the parasite’s life cycle. An example is the Th1/Th2
response dichotomy, which is observed in mice but not in dogs [20,23,24,25]. Even though
these difficulties are intrinsic to canine leishmaniasis vaccine trials, significant differences
between vaccinated and control groups were always observed using LACK gene constructs in
our hands.
IL12 is a proinflammatory cytokine which stimulates cytotoxic T lymphocytes and NK
cells, as well as T helper type 1 (Th1) lymphocytes, leading to IFN-? production. IL12 is able to
enhance lymphocyte proliferation and IFN-? production in L. infantum infected dogs, which
may be an alternative therapy strategy because a protective Th1 response is favoured [28]. In
an attempt to improve efficacy of 200μg pPAL-LACK prime/boost inoculations by the intrana-
sal route, we co-administered pPAL-canIL12-p35 and pPAL-canIL12-p40 plasmid constructs
(20μg each). The experimental infectious challenge was successful because all dogs became
positive to L. infantum over time according to qPCR-based parasite burden analysis and Leish-
mania-specific IgG production (Figs 2–4). Some dogs became sick in both groups and had to
be euthanized before the end of the experiment, while others did not show serious clinical
signs associated to leishmaniasis. Early necropsy procedures were performed after 240 dpi.
This circumstance has been indicated with an asterisk in Figs 1, 3, 4 and 7 (data in S1 Table).
All other dogs were euthanized 300dpi as planned in the experimental design. All end time
point data were processed together. Differences in disease progression within groups are pre-
sumably due to aforementioned individual variability. This causes the lack of statistical signifi-
cance of the differences observed between groups, as explained next. Despite pPAL-LACK
protects [26], no differences in clinical profiles are globally observed when genes encoding for
IL12 subunits are co-administered (Fig 1). Parasite burden is considerably higher in the con-
trol group (GII) than in the experimental group (GI) 240 dpi (Fig 2). A different picture is
observed at the end of the experiment (300 dpi or earlier, as already mentioned): even though
dispersion is higher in the control group (GII) in two out of four target organs, medians are
lower in all of them (Fig 3). In summary, clinical profile follow-up and parasite burden analysis
lead to conclude that no clear protection against the parasite is observed in the experimental
group (GI) compared to the control group (GII).
Similar IgG titles in groups I and II (Fig 4) are not surprising because the parasite is intra-
cellular and consequently, a cellular immune response is required for parasite clearance. In
fact, studies showing protection conferred by the LACK gene presented similar humoral
immune response results [26]. pPAL-LACK/pPAL-canIL12-p35/pPAL-canIL12-p40 cocktail
inoculation was able to induce primary CD4+ activation which decreases over time, as a differ-
ence with the control group, GII (Fig 5). This finding suggests that the pPAL-LACK construct
initially triggers T helper response activation. IFN-? and IL10 levels fluctuate in both groups as
observed in previous experiments [26,27]. In this case, an IFN-? early peak after infection is
observed only in the control group (GII); next, fluctuations alternate between both groups (Fig
Fig 4. Circulating Leishmania infantum-specific IgG levels. IgG levels progressively increased after challenge
reaching the plateau around 120dpi. No significant differences in total IgG, IgG1, and IgG2 levels are observed
between GI (pPAL-LACK/pPAL-canIL12-p35/pPAL-canIL12-p40 group) and GII (infection control group). This is
additional evidence for experimental infectious challenge efficacy in both groups. Immunity to Leishmania spp. is
determined by cellular immune responses.
https://doi.org/10.1371/journal.pone.0212136.g004
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6). Conversely, an IL10 peak occurs earlier in the experimental group, GI (Fig 7). In principle,
IL10 is a typical Th2 cytokine, whereas IFN-? is related to a Th1 response. The Th1/Th2 pro-
tection/susceptibility dichotomy has been demonstrated in the experimental murine model
against L.major infection (reviewed in [20]). However, fluctuations were observed in previous
Fig 5. Lymphoblastic transformation test (LTT). CD4+-proliferation against the LACK protein is observed only in group GI (pPAL-LACK/
pPAL-canIL12-p35/pPAL-canIL12-p40). Proliferation decreases 180, 240, and 300dpi. Several dogs had to be euthanized before the end of the
experiment (after the 240dpi time point) for ethical reasons.
https://doi.org/10.1371/journal.pone.0212136.g005
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experiments using only the LACK gene [26,27] and in this study co-administering IL12 sub-
unit genes. This is in agreement with a balanced Th1/Th2 response in the canine model as the
hypothetical key event leading to protection. Such balanced response occurs when there is no
relevant IFN-? or IL10 excess [23,24,25]. As cytokine fluctuations have been observed in both
Fig 6. IFN-? concentration in LTT supernatants. A specific commercially available ELISA procedure was used to
determine IFN-? concentration (pg/mL) in LTT supernatants, which had been immediately stored at -20˚C after
separation from cells. IFN-? fluctuates in LTT supernatants from GI dogs (pPAL-LACK/pPAL-canIL12-p35/pPAL-
canIL12-p40), and gradually decrease in the control group (GII). At the beginning (21dpi), IFN-? is observed only in
GII. Several dogs had to be euthanized before the end of the experiment (after the 240dpi time point) for ethical
reasons.
https://doi.org/10.1371/journal.pone.0212136.g006
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groups configuring this experiment (Figs 6 and 7) and is not a distinctive feature compared to
previous experiments [26,27], we infer that this is not the factor causing IL12 failure as an
adjuvant in this case. A recombinant protein preparation including IL12 and a mixture of cys-
teine peptidases did not protect dogs against L. infantum either [43]. Therefore, vaccine type
does not seem to be the cause of failure. We propose two possible causes of pPAL-canIL12-p35
Fig 7. IL10 levels in LTT supernatants. A specific commercially available ELISA procedure was used to determine
IL10 concentration (pg/mL) in LTT supernatants, which had been immediately stored at -20˚C after separation from
cells. The IL10 peak is observed earlier in GI (pPAL-LACK/pPAL-canIL12-p35/pPAL-canIL12-p40) than in GII
(infection control group). Several dogs had to be euthanized before the end of the experiment (after the 240dpi time
point) for ethical reasons.
https://doi.org/10.1371/journal.pone.0212136.g007
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and pPAL-canIL12-p40 constructs acting as inhibitors of protection conferred by the pPAL--
LACK vaccine: i) IL12 is a good cytokine therapy candidate [28] but may not function as a
Th1 immune response enhancer in uninfected dogs; and ii) amounts of IL12 subunit genes
administered to dogs by the intranasal route may not be adequate and may cause unexpected
immune response de-regulation counteracting pPAL-LACK vaccine protection effects. In any
case, using pPAL-LACK vaccine alone has led to much more promising results in canine leish-
maniasis vaccination trials [26], as well as heterologous regimes using recombinant vaccinia
viruses [27,34]. Poot et al. also hypothesized that dose and timing may be important for IL12
administration [43]. In view of all discussed data, future trials trying to optimize amounts of
IL12 subunit-encoding genes would not lead to successful results improving pPAL-LACK pro-
tection in our opinion. This would probably cause worthless use of a lot expenses in human
and material resources, as well as outstanding use of Beagle dogs, breaking the reduction prin-
ciple in animal experimentation. This observation should not be generalized for other vaccine
candidates against the same parasite or other pathogens. Comparing results obtained using an
antigen without and with IL12 would be useful for case-by-case risk-benefit prediction of
future IL12 dose and timing optimization experiments.
Finally, it is important to remark that the experiment presented herein is an example of the
substantial differences in biology and pathology between Leishmania species and parasite-host
pairs (fundamentally, L.major-mice and L. infantum-dogs). In fact, successful adjuvant effects
of IL12 observed in protection experiments against L.major infection in mice has not been
observed in dogs until now. Another example of lack of correspondence between models is
Th1/Th2 response dichotomy, which has been clearly observed only in mice.
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